Association Between Screening Behaviors and Lung Cancer Spectrum
A Multicenter, Prospective, Observational Study on the Association Between Real-World Lung Cancer Screening Behaviors and Lung Cancer Disease Spectrum
The goal of this observational study is to describe the clinical epidemiological characteristics and disease spectrum distribution of newly diagnosed primary lung cancer patients in a real-world setting. The main questions it aims to answer are:
What is the current status of lung cancer epidemiology, including age, gender, smoking history, and pathological subtype distribution? How do different lung cancer screening behaviors (e.g., overscreening, underscreening, guideline-concordant, and precision screening) influence the capture rate of the "curative time window" (defined as adenocarcinoma in situ (AIS)/minimally invasive adenocarcinoma (MIA) or pure Ground-Glass Nodules (GGNs) stage)? What are the economic costs and cumulative radiation exposure associated with these different screening patterns? Researchers will compare these screening behavior groups to evaluate the efficacy of the "low-age, low-frequency" screening strategy in capturing early-stage lung cancer.
Participants will be asked to:
Provide their medical history and detailed records of pre-diagnosis lung cancer screening (including CT scan history).
Allow researchers to collect and analyze their clinical, pathological, and radiological data from hospital records and medical databases.
Complete a questionnaire regarding their screening history and health-related behaviors.
Studie Overzicht
Toestand
Conditie
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studie Locaties
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200032
- Werving
- Fudan University Cancer Center
-
Contact:
- Chen Haiquan, MD
- Telefoonnummer: 1707 +86-21 64175590
- E-mail: hqchen1@yahoo.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Kind
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Histologically confirmed primary lung cancer within the past year (surgical or biopsy pathology).
- Patients capable of clearly recalling or providing medical and physical examination history prior to diagnosis.
Exclusion Criteria:
- Recurrent lung cancer or metastatic lung tumors.
- Severe lack of critical clinical data (e.g., inability to provide pathological type or stage).
- Patients with cognitive impairment or severe mental illness who cannot cooperate with the questionnaire.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Epidemiological Characteristics
Tijdsspanne: through study completion, an average of 1 year
|
Distribution of age, gender, smoking history, and pathological subtypes.
|
through study completion, an average of 1 year
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Curative Time Window Capture Rate
Tijdsspanne: through study completion, an average of 1 year
|
The proportion of tumors captured at the AIS/MIA or pure GGN stage
|
through study completion, an average of 1 year
|
|
Socioeconomic Indicators
Tijdsspanne: through study completion, an average of 1 year
|
This measure assesses the total direct medical costs.
Data are collected through a combination of hospital electronic medical records (EMR) and a structured patient questionnaire.
Costs include pre-diagnosis examination expenses (e.g., CT scans, consultations) and post-diagnosis treatment expenses (e.g., surgery, hospitalization, systemic therapy), calculated based on standardized clinical billing data.
|
through study completion, an average of 1 year
|
|
Cumulative Radiation Dose
Tijdsspanne: through study completion, an average of 1 year
|
through study completion, an average of 1 year
|
|
|
Screening Efficacy
Tijdsspanne: through study completion, an average of 1 year
|
This measure evaluates the efficacy of screening behaviors in detecting early-stage lung cancer.
Data are derived from hospital clinical databases and a structured patient questionnaire.
Key parameters include the frequency of pre-diagnosis CT scans, age at first screening, and pathological stage at diagnosis.
The association is assessed using correlation analysis and logistic regression models to compare the capture rate of the "curative time window" (AIS/MIA/pure GGN) across different screening groups.
|
through study completion, an average of 1 year
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- ECTOP-1038
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .